• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.91
  • VXN 16.64
  • VXO 14.31
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

IMMU (Immunomedics Inc.)
Last Trade 18.35 Dividend/Share 0 PE Ratio -22.11
Date March 20-2019 Dividend Yield 0.000 Return on Assets -59.46
Change -0.45 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -1.75 Price/Sale 4,143.739
Ask 0 LatestEPS Date 2018-12-31 Price to Book 13.49
Volume 80801 EPS ttm -0.830 Institutional % 120.8
Avg Volume 2.52M Shares Outstanding 190.96M Insider % null
Open 18.72 Float 188.71M Short Ratio null
Prev Close 18.8 Return On Equity -117.71 5 Year Change % 2.998
High 18.89 Consensus EPS -0.2 2 Year Change % 1.931
Low 17.88 No. of Estimate 3.000 1 Year Change % 0.150
52 Week High 27.33 EPS Surprise $ null YTD Change % 0.225
52 Week Low 11.55 EPS Surprise Percent -70 6 Month Change % -0.186
52 Week Change 21.212 EBITDA 0M 3 Month Change % 0.027
50 Day MA 15.8436 Revenue 0M 1 Month Change % 0.290
200 Day MA Gross Profit 0M 5 Day Change % 0.023
Market Cap 3590.05M Cash 0M 30 Day Change % 0.242
Beta 2.091811 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. The company?s preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, ?LeukoScan?, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.